Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus - PubMed (original) (raw)

Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus

A J Swaak et al. Ann Rheum Dis. 1986 May.

Abstract

In a prospective study of 143 patients with systemic lupus erythematosus (SLE) the relation between clinical exacerbations, anti-dsDNA levels, and serum levels of complement components, C1q, C4, C3, C5, and C9 was investigated. In 33 out of these 143 patients a major clinical exacerbation of the disease developed. Evaluation of anti-dsDNA levels in relation to disease activity confirmed our earlier finding that anti-dsDNA levels rose before a major exacerbation and decreased after it. In the remaining 110 SLE patients a nearly constant anti-dsDNA level was seen, but none of these patients experienced a major exacerbation. In the 21 SLE patients who developed deterioration in renal function a decrease of C4 followed by decreases of C1q and C3 levels was seen first, starting about 25 to 20 weeks before the first signs of renal involvement. In the 12 SLE patients who developed an exacerbation without renal involvement an inconsistent profile of the complement components C4, C1q, and C3 was observed. C5 levels were hardly affected at all, while C9 levels were in general higher than normal during the exacerbation, irrespective of the type of exacerbation. These results show that, by following the complement and anti-dsDNA profiles, not only can exacerbations be predicted but also a pointer can be obtained about the pattern of disease well before the first clinical signs of an exacerbation appear.

PubMed Disclaimer

Similar articles

• Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4.
  Julkunen H, Ekblom-Kullberg S, Miettinen A. Julkunen H, et al. Rheumatol Int. 2012 Aug;32(8):2445-51. doi: 10.1007/s00296-011-1962-3. Epub 2011 Jun 26. Rheumatol Int. 2012. PMID: 21706294
• Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study.
  ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. ter Borg EJ, et al. Arthritis Rheum. 1990 May;33(5):634-43. doi: 10.1002/art.1780330505. Arthritis Rheum. 1990. PMID: 2346519
• Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus.
  Mok CC, Ho LY, Leung HW, Wong LG. Mok CC, et al. Transl Res. 2010 Dec;156(6):320-5. doi: 10.1016/j.trsl.2010.07.009. Epub 2010 Aug 20. Transl Res. 2010. PMID: 21078493
• Clinical significance of antibodies to double stranded DNA (dsDNA) for systemic lupus erythematosus (SLE).
  Swaak T, Smeenk R. Swaak T, et al. Clin Rheumatol. 1987 Jun;6 Suppl 1:56-73. doi: 10.1007/BF02200721. Clin Rheumatol. 1987. PMID: 3304800 Review.
• The kidney in systemic lupus erythematosus.
  Cameron JS, Turner DR, Vosnides G, Leibowitz S, Lessof MH, Ogg CS, Chantler C, Brown CB. Cameron JS, et al. Perspect Nephrol Hypertens. 1977;6:41-81. Perspect Nephrol Hypertens. 1977. PMID: 320552 Review. No abstract available.

Cited by

• Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus.
  Siegert CE, Daha MR, Tseng CM, Coremans IE, van Es LA, Breedveld FC. Siegert CE, et al. Ann Rheum Dis. 1993 Dec;52(12):851-6. doi: 10.1136/ard.52.12.851. Ann Rheum Dis. 1993. PMID: 8311534 Free PMC article.
• Systemic lupus erythematosus--changing disease patterns in the disease course. Dutch experience with 110 patients studied prospectively.
  Swaak AJ, Bronsveld W, Nieuwenhuys EJ, Nossent JC, Smeenk RJ. Swaak AJ, et al. Rheumatol Int. 1991;10(6):241-4. doi: 10.1007/BF02274886. Rheumatol Int. 1991. PMID: 2041982
• Hypocomplementemia as a Risk Factor for Organ Damage Accrual in Patients with Systemic Lupus Erythematosus.
  Raymond W, Eilertsen G, Nossent J. Raymond W, et al. J Immunol Res. 2018 Dec 30;2018:8051972. doi: 10.1155/2018/8051972. eCollection 2018. J Immunol Res. 2018. PMID: 30687766 Free PMC article.
• Predictors of incident proteinuria among patients with SLE.
  Duarte-García A, Barr E, Magder LS, Petri M. Duarte-García A, et al. Lupus Sci Med. 2017 May 22;4(1):e000200. doi: 10.1136/lupus-2016-000200. eCollection 2017. Lupus Sci Med. 2017. PMID: 29177060 Free PMC article.
• Significance of low molecular weight C1q in systemic lupus erythematosus.
  Hoekzema R, Swaak AJ, Brouwer MC, van Rooijen A, Nieuwenhuys EJ, Hack CE. Hoekzema R, et al. Ann Rheum Dis. 1990 Sep;49(9):698-704. doi: 10.1136/ard.49.9.698. Ann Rheum Dis. 1990. PMID: 2241286 Free PMC article.

References

1. 1. J Clin Invest. 1967 Dec;46(12):2021-34 - PubMed
2. 1. N Engl J Med. 1968 Mar 7;278(10):533-8 - PubMed
3. 1. Virology. 1968 Apr;34(4):738-47 - PubMed
4. 1. Clin Exp Immunol. 1969 Feb;4(2):191-202 - PubMed
5. 1. Ann Intern Med. 1971 Oct;75(4):555-60 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • HighWire
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal